-
Application value of composite echocardiography technique in detecting
cardiotoxicity caused by lymphoma chemotherapy
- Xue Jing, Zhang Zhoulong, Chen Shengjiang, Yuan Xiaozhi, Duan Like, Wang Huifen
-
2022, 28(16):
2236-2240.
DOI: 10.3760/cma.j.issn.1007-1245.2022.16.004
-
Asbtract
(
)
-
References |
Related Articles |
Metrics
Objective To investigate the application value of composite echocardiography
technique in dynamically monitoring cardiotoxicity caused by lymphoma
chemotherapy. Methods A total of 28
non-Hodgkin lymphoma patients underwent chemotherapy in The First Affiliated
Hospital of Henan University of Science and Technology, including 12 males and
16 females, aged (51.22±10.17) years; 30 healthy volunteers were selected as
controls during the same period, including 12 males and 18 females, aged
(50.19±12.06) years. Real-time two-dimensional echocardiography (RT-2DE),
tissue Doppler imaging (TDI), and two-dimensional speck-tracking imaging
(2D-STI) were used to detect the cardiac function indexes in all patients after
2, 4, and 6 cycles of chemotherapy. The left ventricular ejection fraction
(LVEF), left ventricular anterior diameter (LV), left atrial anterior diameter
(LA), peak E, peak A, E/A, mitral peak E deceleration time (DT), the ratio of
early diastolic velocity of blood flow spectrum (E) to early diastolic peak
velocity of mitral annulus (e'), left ventricular global circumferential strain
(LVGCS), left ventricular global radial strain (LVGRS), left ventricular global
longitudinal strain (LVGLS), and peak left ventricular twist angle (LVPtw) were
observed and compared in both groups. Independent sample t test or one-way ANOVA was used for the measurement data, and
Chi-square test was used for the count data. Results There were no statistically significant differences in the LVEF, LV, LA,
peak E, peak A, and E/A between the chemotherapy group and the control group
after 2 and 4 cycles of chemotherapy (all P>0.05).
There was no statistically significant difference in the DT between the
chemotherapy group and the control group after 2 cycles of chemotherapy (P>0.05), but there was a
statistically significant difference after 4 cycles of chemotherapy
[(213.16±21.23) ms vs. (181.26±20.23) ms] (P<0.05).
After 6 cycles of chemotherapy, the LVEF, LV, LA, peak E, peak A, E/A, and DT
in the chemotherapy group were (49.01±4.12)%, (56.68±4.32) mm, (43.64±4.02) mm,
(78.36±12.20) cm/s, (90.96±12.61) cm/s, (0.76±0.21), and (256.23±32.14) ms,
with statistically significant differences compared with those in the control
group (all P<0.05). There were no
statistically significant differences in the e' and E/e' between the
chemotherapy group and the control group after 2 cycles of chemotherapy (both P>0.05). In the chemotherapy group,
the e' was (8.22±1.27) cm/s and the E/e' was (18.17±3.12) after 4 cycles of
chemotherapy, the e' was (4.29±2.17) cm/s and the E/e' was (20.17±4.06) after 6
cycles of chemotherapy, with statistically significant differences compared
with those in the control group (all P<0.05).
There were statistically significant differences in the LVGRS, LVGCS, LVGLS,
and LVPtw between the chemotherapy group and the control group after 2, 4, and
6 cycles of chemotherapy (all P<0.05). Conclusion Chemotherapy with
anthracycline for tumor patients can lead to cardiotoxicity, and RT-2DE
combined with TDI and 2D-STI can detect the cardiotoxicity caused by
chemotherapy earlier and more sensitively, which is of great significance for
guiding clinical practice.